sipuleucel-T

medicine

Also known as: Provenge

Written by

The Information Architects of Encyclopaedia Britannica

Last updated

July 17, 2026

Quick Summary

Sipuleucel-T is a type of immunotherapy used to treat prostate cancer. It works by activating a patient's own immune system to fight cancer cells. This is achieved by collecting dendritic cells from the patient, which are then cultured in a lab with a substance (prostatic acid phosphatase, or PAP) that is overproduced by prostate cancer cells. These activated dendritic cells are then infused back into the patient. The goal is to stimulate T cells to recognize and attack cancer cells that produce PAP, leading to a more effective immune response against the cancer.1

Summary created from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.

2 Britannica Sources

Ask Britannica AI about this topic

Britannica doesn't have a full article on this topic, so we've curated a list of our relevant coverage.

prostate cancer
Sipuleucel-T
…with an agent known as sipuleucel-T (Provenge), which is designed to activate the immune system to attack cancer cells. Sipuleucel-T was approved by the U.S. Food and Drug Administration in 2010, becoming the first immunotherapeutic agent available for the treatment of prostate cancer. Sipuleucel-T is tailored specifically for each patient.…
Read More
…with an agent known as sipuleucel-T (Provenge), which is designed to activate the immune system to attack cancer cells. Sipuleucel-T was approved by the U.S. Food and Drug Administration in 2010, becoming the first immunotherapeutic agent available for the treatment of prostate cancer. Sipuleucel-T is tailored specifically for each patient.…
Read More

Ralph M. Steinman
The agent sipuleucel-T, which was developed based on Steinman’s discoveries and is used in the treatment of prostate cancer, was the first dendritic cell vaccine and first cancer vaccine to be approved by the U.S. Food and Drug Administration. Sipuleucel-T is manufactured by collecting antigen-presenting cells from…
Read More
The agent sipuleucel-T, which was developed based on Steinman’s discoveries and is used in the treatment of prostate cancer, was the first dendritic cell vaccine and first cancer vaccine to be approved by the U.S. Food and Drug Administration. Sipuleucel-T is manufactured by collecting antigen-presenting cells from…
Read More